CryoCath clarification
This article was originally published in The Gray Sheet
Executive Summary
FDA-approved labeling for CryoCath's Freezor ablation catheter, PMA-approved April 22, includes directions for performing cryomapping prior to cryoablation of atrioventricular node re-entry tachycardia. However, the Freezor's instructions for use do not list cryomapping as a specific indication, as was reported in "The Gray Sheet" (April 28, p. 5)...
You may also be interested in...
Freezor modification
CryoCath's FreezorXtra, the larger version of the Freezor cryoablation catheter, is now available to a limited number of U.S. electrophysiologists after earning 510(k) clearance for epicardial ablation, the Montreal company announces May 8. Until the company's clinical advisory board completes a comprehensive dissemination plan later this year, the device will be targeted to operators familiar with the epicardial arrhythmia ablation technique pioneered by Eduardo Sosa, MD, University of Sao Paulo. On April 22, Freezor was approved for treating atrioventricular node re-entry tachycardia (1"The Gray Sheet" May 5, 2003, In Brief)...
Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: